Friday, June 16, 2017 6:17:36 AM
In March, Empery Asset Management bought 575,000 shares of AEMD from the company in a private placement for $3.50. At the time, the stock was trading around $3.85 or so (which at the time upset current shareholders because the stock was sold at an obvious discount). Today the stock trades at $2.26.
Anyone who has followed AEMD closely over the years (or followed other small/penny stocks who use the same scheme) know that without a doubt, EMPERY IS GOING TO MAKE VERY GOOD MONEY ON THEIR INVESTMENT, WITHIN A FEW MONTHS TIME. Just go back and research the Roth placements. same pattern - Roth bought at a slight discount to market, a few weeks or months later some "new" news is released and the stock price and volume pops, giving Roth all the liquidity they need to exit with 50%, 100%, 200% profits.
You see, Empery didn't make an investment in AEMD on the same information you or I are using to make a decision; they invested because they already know the news that will be announced on June 21st is GOOD NEWS. The stock is going to pop to somewhere above $4 and Empery will exit with their money, expediting the corresponding fall of the stock in the following few days.
People who bought on the news (the average Joes) are left with way over-priced shares and a stock price dropping like a rock for no apparent reason. Sound familiar? To win, you have to beat them at their own game and buy in advance of the coming run-up.
Just my humble opinion - I could be wrong. GLTA
Recent AEMD News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 12:01:08 PM
- Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India • PR Newswire (US) • 09/19/2024 12:01:00 PM
- Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial • PR Newswire (US) • 09/16/2024 12:01:00 PM
- Aethlon Medical to Present at the Life Sciences Investor Forum September 19th • GlobeNewswire Inc. • 09/13/2024 12:35:00 PM
- Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys • PR Newswire (US) • 08/27/2024 12:01:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/15/2024 08:34:03 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/15/2024 08:32:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/15/2024 08:30:33 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 08/15/2024 08:15:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 09:10:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:15:21 PM
- Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update • PR Newswire (US) • 08/14/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 12:01:08 PM
- Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial • PR Newswire (US) • 08/12/2024 12:01:00 PM
- Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024 • PR Newswire (US) • 08/06/2024 01:12:00 PM
- Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update • PR Newswire (US) • 06/27/2024 08:15:00 PM
- Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024 • PR Newswire (US) • 06/21/2024 12:01:00 PM
- Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial • PR Newswire (US) • 06/18/2024 12:01:00 PM
- Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies • PR Newswire (US) • 06/03/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 05:24:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:05:28 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/16/2024 08:05:23 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM